SHG Provides Compensation Analysis to GB Sciences, Inc.
SHG is pleased to announce it has completed a detailed compensation analysis for GB Sciences, Inc., for the benefit of attracting and retaining the senior leadership team. Our analysis was used among management and its advisors.
About GB Sciences, Inc.
GB Sciences is a biopharmaceutical and cannabinoid-based drug development company whose goal is to create patented formulations for safe, standardized, cannabinoid therapies that target a variety of medical conditions in both the pharmaceutical and wellness markets. To learn more about GB Sciences please visit Home - GB Sciences.
Learn about Randall Hooper, SHG's CVA. Explore his journey from a young entrepreneur and private equity roles to his expertise in business valuation and planning.
Navigate M&A successfully. Learn when to engage an M&A advisor for optimal timing, valuation, and deal success. Expert insights from SHG.
